Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Zynerba Pharmaceuticals, Inc. (ZYNE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.0600-0.0700 (-1.69%)
At close: 4:00PM EDT
4.0700 +0.01 (+0.25%)
After hours: 05:50PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close4.1300
Open4.1300
Bid4.0000 x 1100
Ask4.0700 x 1200
Day's Range4.0400 - 4.1300
52 Week Range3.1500 - 9.0000
Volume1,883,370
Avg. Volume1,720,633
Market Cap167.481M
Beta (5Y Monthly)2.42
PE Ratio (TTM)N/A
EPS (TTM)-1.0820
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ZYNE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Zynerba Pharmaceuticals, Inc.
    CARA: Lowering target price to $11.00CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    10 days agoArgus Research
View more
  • GlobeNewswire

    Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition

    DEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 American Academy of Pediatrics (AAP) National Conference & Exhibition, which will be held virtually from October 8-11, 2021. A copy of the poster titled, “Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol

  • GlobeNewswire

    Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

    DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 11:20 a.m. ET. Investors interested in arranging a virtua

  • GlobeNewswire

    Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

    Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announces the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-cent

Advertisement
Advertisement